Summary
Two phase I trials, each involving 16 healthy adult volunteers, were performed to investigate possible interactions between grepafloxacin and theophylline or warfarin. In the theophylline study, grepafloxacin 600mg was administered once daily for 10 days to 12 volunteers who were receiving a maintenance dose of theophylline. This dose of theophylline was designed to produce mean serum theophylline concentrations of 7.5 mg/L; 4 volunteers received theophylline plus placebo. Pharmacokinetic parameters of theophylline were determined before grepafloxacin treatment and on day 10 of grepafloxacin or placebo administration. Peak theophylline concentrations and the area under the concentration-time curve increased significantly during grepafloxacin treatment, and apparent total clearance of theophylline was reduced by approximately 50%. No changes were observed in the placebo group and theophylline appeared to have no effect on the pharmacokinetics of grepafloxacin. In the warfarin study, grepafloxacin 600mg was given once daily for 14 days to volunteers receiving a maintenance dose of warfarin. Warfarin was discontinued during the last 4 days of grepafloxacin administration. The pharmacodynamics of warfarin did not change after administration of grepafloxacin. Similarly, warfarin had no significant effect on the pharmacokinetics of grepafloxacin. We conclude that during treatment with grepafloxacin maintenance, doses of theophylline should be reduced by 50%, and we recommend that serum concentrations of theophylline be monitored during treatment with grepafloxacin. However, no dose adjustment is necessary for grepafloxacin when it is coadministered with theophylline, and dose adjustment does not seem to be required in concomitant treatment with grepafloxacin and warfarin.
Similar content being viewed by others
References
Janknegt R. Drug interactions with fluoroquinolones. J Antimicrob Chemother 1990; 6 Suppl. D: 7–29
Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991; 10: 267–74
Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf 1992; 7: 268–81
Hendeles L, Weinberger M, Johnson G. Monitoring serum theophylline levels. Clin Pharmacokinet 1978; 9: 294–312
Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434–61
Sörgel F, Mahr G, Granneman GR, et al. Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22 Suppl. 1: 65–74
Stuck AE, Kim DK, Frey FJ. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 116–31
Leor J, Matatzki S. Ofloxacin and warfarin. Ann Intern Med 1988; 109: 761
Linville T, Matanin D. Norfloxacin and warfarin. Ann Intern Med 1989; 110: 751–2
Kamada AK. Possible interaction between ciprofloxacin and warfarin. Drug Intell Clin Pharm 1990; 24: 27–8
Nichols WL, Bowie EJ. Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the International Normalized Ratio system. Mayo Clin Proc 1993; 68: 897–8
Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984; 288: 1268–70
Miller D, Brown M. Predicting warfarin and maintenance dosage based on initial response. Am J Hosp Pharm 1979; 36: 1351–5
Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997; 33 Suppl. 1: 1–8
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982; 409–16
Bressolle F, Gonçalves F, Gouby A, et al. Pefloxacin clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 418–46
Akiyama H, Odomi M. Report 8850. Metabolism of 14C-OPC-17116 by human cytochrome P450 isoforms expressed by recombinant vaccinia virus
Efthymiopoulos C, Bramer SL, Maroli A. Effect of age and gender on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997; 33 Suppl. 1: 9–17
Cook PJ, Andrews JM, Wise R, et al. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317–26
Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32–6
Toon S, Hopkins KJ, Garstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987; 42: 33–41
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Efthymiopoulos, C., Bramer, S.L., Maroli, A. et al. Theophylline and Warfarin Interaction Studies with Grepafloxacin. Clin-Pharmacokinet 33 (Suppl 1), 39–46 (1997). https://doi.org/10.2165/00003088-199700331-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199700331-00008